DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation
of pretransplant blood transfusions in cadaver kidney
recipients. Transplantation, 1997, 63:964–967.
Ortho Multicenter Transplant Study Group. A randomized clinical
trial of OKT3 monoclonal antibody for acute rejection of
cadaveric renal transplants. N Engl J Med, 1985, 313:
337–342.
Paravar T, Lee DJ. Thalidomide: Mechanism of action. Int Rev
Immunol, 2008, 27:111–135.
Patard JJ, Saint F, Velotti F, et al. Immune response following
intravesical bacillus Calmette-Guérin instillations in superficial
bladder cancer: A review. Urol Res, 1998, 26:155–159.
Pattison JM, Sibley RK, Krensky AM. Mechanisms of allograft
rejection. In: Neilson EG, Couser WG, eds. Immunologic
Renal Diseases. Philadelphia, Lippincott-Raven, 1997,
pp. 331–354.
Pescovitz MD, Bumgardner GL, Gaston RS, et al. Addition of
daclizumab to mycophenolate mofetil, cyclosporine, and
steroids in renal transplantation: Pharmacokinetics, safety, and
efficacy. Clin Transplant, 2003, 17:511–517.
Peterec SM. Management of neonatal Rh disease. Clin Perinatol,
1995, 22:561–592.
Polman CH, O’Connor PW, Havrdova E, et al. A randomized,
placebo-controlled trial of natalizumab for relapsing multiple
sclerosis. N Engl J Med, 2006, 354:899–910.
Prakash A, Jarvis B. Leflunomide: A review of its use in active
rheumatoid arthritis. Drugs, 1999, 58:1137–1164.
Ransohoff RM. Cellular responses to interferons and other
cytokines: The JAK-STAT paradigm. N Engl J Med, 1998,
338:616–618.
Regan JF, Campbell K, Van Smith L, et al. Sensitization following
Thymoglobulin and Atgam rejection therapy as determined
with a rapid enzyme-linked immunosorbent assay. US
Thymoglobulin Multi-Center Study Group. Transplant
Immunol, 1999, 7:115–121.
Salmela K, Wramner L, Ekberg H, et al. A randomized multicenter
trial of the anti-ICAM-1 monoclonal antibody
(enlimomab) for the prevention of acute rejection and delayed
onset of graft function in cadaveric renal transplantation: A
report of the European Anti-ICAM-1 Renal Transplant Study
Group. Transplantation, 1999, 67:729–736.
Schreiber SL, Crabtree GR. The mechanism of action of
cyclosporin A and FK506. Immunol Today, 1992, 13:136–142.
Sinkovics JG, Horvath JC. Vaccination against human cancers
[review]. Int J Oncol, 2000, 16:81–96.
Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function
and case nephropathy associated with tacrolimus plus
rapamycin use. J Am Soc Nephrol, 2003, 14:1037–1045.
Starzl TE, Demetris AJ, Murase N, et al. Chimerism after organ
transplantation. Curr Opin Nephrol Hypertens, 1997, 6:
292–298.
Steinman L. Immune therapy for autoiummune diseases.
Science, 2004, 305:212–216.
Suthanthiran M, Morris RE, Strom TB. Immunosuppressants:
Cellular and molecular mechanisms of action. Am J Kidney
Dis, 1996, 28:159–172.
Szczech LA, Berlin JA, Aradhye S, et al. Effect of antilymphocyte
induction therapy on renal allograft survival: A
meta-analysis. J Am Soc Nephrol, 1997, 8:1771–1777.
Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: A current
overview. Cell, 1993, 73:5–8.
Tarte K, Klein B. Dendritic cell-based vaccine: A promising
approach for cancer immunotherapy. Leukemia, 1999, 13:
653–663.
Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin
1 inhibitor rilonacept in treatment of chronic gouty arthritis:
results of a placebo-controlled, monosequence crossover, nonrandomised,
single-blind pilot study. Ann Rheum Dis, 2009,
68:1613–1617.
Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the
immune system: Turning lymphocytes off. Science, 1998,
280:243–248.
Vincenti F, Kirk AD. What’s next in the pipeline. Am J
Transplant, 2008, 8:1972–1981.
Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor
blockade with daclizumab to prevent acute rejection in renal
transplantation. Daclizumab Triple Therapy Study Group.
N Engl J Med, 1998, 338:161–165.
Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade
with belatacept in renal transplantation. N Engl J Med, 2005,
353:770–781.
Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized
open-label multicenter trial of efalizumab, a humanized
anti-CD11a, anti-LFA-1 in renal transplantation. Am J
Transplant, 2007, 7:1770–1777.
Vincenti F, Mendez R, Rajagopalan PR, et al. A phase I/II trial
of anti-CD11a monoclonal antibody in renal transplantation.
Am J Transplant, 2001, 1(suppl):276.
Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter
study of steroid avoidance, early steroid withdrawal
or standard steroid therapy in kidney transplant recipients. Am
J Transplant, 2008, 8:307–316.
Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous
immune globulin for densensitization during renal
transplantation. N Engl J Med, 2008, 359:242–251.
Wall WJ. Use of antilymphocyte induction therapy in liver transplantation.
Liver Transplant Surg, 1999, 5:S64–S70.
Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: A potent new
immunosuppressant for liver transplantation. Transplantation,
1999, 67:505–509.
Weaver TA, Charafeddine AH, Kirk AD. Costimulation blockade:
Towards clinical application. Front Biosci, 2008,
13:2120–2139.
Whittington R, Faulds D. Interleukin-2. A review of its pharmacological
properties and therapeutic use in patients with cancer.
Drugs, 1993, 46:446–514.
Wiseman LR, Faulds D. Daclizumab: A review of its use in the
prevention of acute rejection in renal transplant recipients.
Drugs, 1999, 58:1029–1042.
Zachary AA, Montgomery RA, Ratner LE, et al. Specific and
durable elimination of antibody to donor HLA antigens in renaltransplant
patients. Transplantation, 2003, 76:1519–1525.
Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable
renal transplant patients after multiple oral dose administration.
J Clin Pharmacol, 1997, 37:405–415.
1029
CHAPTER 35
IMMUNOSUPPRESSANTS, TOLEROGENS, AND IMMUNOSTIMULANTS